Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III double-blind randomized trial of 9-valent HPV vaccine versus quadrivalent HPV vaccine in 20–45-year-old Chinese women
CTR20190587Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Sep 2019
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in Cervical Cancer (CC), Vulval carcinoma, vaginal cancer, anal cancer, cervical intraepithelial neoplasia (CIN), sponsored by Merck & Co.. Started Sep 2019; status: active.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
Cervical Cancer (CC)Vulval carcinomavaginal canceranal cancercervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on CTR20190587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190587.